BOSTON—A top U.S. Food and Drug Administration official testified on Nov. 19 that the agency has concerns about drugs made by compounding pharmacies and still sees problems with them six years after a fungal meningitis outbreak tied to a Massachusetts pharmacy killed 76 people.
Janet Woodcock, who heads the FDA’s pharmaceuticals division, testified in Boston federal court that she had never seen an outbreak like the one New England Compounding Center’s mold-tainted steroids caused in 2012.
